Australian Eileen Therapeutics to conduct clinical trial of anti-tumor drug in Russia Eileen Therapeutics of Australia has received approval from the Russian Ministry of Health to conduct a phase I clinical trial (CT) of an anti-tumor drug named ZE74-0282-0002. The relevant information has been published in the Registry of Approved Clinical Trials of GRLS. A study of the frequency of dose-limiting toxicities during cycle 1 (ie, C1D1 to C1D28) is planned. The recommended dose for phase II will be determined in expansion cohorts where efficacy, safety, pharmacokinetics and pharmacodynamics are evaluated together. ZE74-0282-0002 is a highly selective inhibitor of Janus kinase 2 (JAK2) V617F mutant. It is designed to be used to treat myelofibrative neoplasms, including myelofibrosis. As part of the clinical trial, the drug will be used in powder form to prepare a 75 mg suspension. Up to 30 people will participate. Clinical trials are planned in nine Russian medical institutions. Among them we can name the Leningrad Design Bureau, the Moscow International Scientific and Research Center named after him. S. P. Botkin, National Center for Medical Research in Radiology, Research Institute of Hematology and Kirov Blood Transfusion, FMBA, National Center for Medical Research named after V.A. Almazova and another number. As Vademecum explains, Eileen and subsidiary Lomond Therapeutics are currently conducting four more clinical trials of three of their own cancer drugs in Russia. For example, Lonitoclax is being studied for the treatment of acute myeloid leukemia (AML) and small lymphocytic lymphoma. A clinical trial of the drug was also conducted for the treatment of relapsed or refractory AML with the FLT3 mutation. Read us in Max Telegram VK.

Australian Eileen Therapeutics to conduct clinical trial of anti-tumor drug in Russia Eileen Therapeutics of Australia has received approval from the Russian Ministry of Health to conduct a phase I clinical trial (CT) of an anti-tumor drug named ZE74-0282-0002. The relevant information has been published in the Registry of Approved Clinical Trials of GRLS. A study of the frequency of dose-limiting toxicities during cycle 1 (ie, C1D1 to C1D28) is planned. The recommended dose for phase II will be determined in expansion cohorts where efficacy, safety, pharmacokinetics and pharmacodynamics are evaluated together. ZE74-0282-0002 is a highly selective inhibitor of Janus kinase 2 (JAK2) V617F mutant. It is designed to be used to treat myelofibrative neoplasms, including myelofibrosis. As part of the clinical trial, the drug will be used in powder form to prepare a 75 mg suspension. Up to 30 people will participate. Clinical trials are planned in nine Russian medical institutions. Among them we can name the Leningrad Design Bureau, the Moscow International Scientific and Research Center named after him. S. P. Botkin, National Center for Medical Research in Radiology, Research Institute of Hematology and Kirov Blood Transfusion, FMBA, National Center for Medical Research named after V.A. Almazova and another number. As Vademecum explains, Eileen and subsidiary Lomond Therapeutics are currently conducting four more clinical trials of three of their own cancer drugs in Russia. For example, Lonitoclax is being studied for the treatment of acute myeloid leukemia (AML) and small lymphocytic lymphoma. A clinical trial of the drug was also conducted for the treatment of relapsed or refractory AML with the FLT3 mutation. Read us in Max Telegram VK.